AKBA Q3 2017 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M

Gross Profit

-$17M-42.2% margin

Operating Income

-$24M-58.6% margin

Net Income

-$23M-56.0% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+44.8%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$339M

Total Liabilities

$239M

Stockholders' Equity

$100M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$0	—
Gross Profit	-$17M	-$31M	+44.2%
Operating Income	-$24M	-$36M	+33.2%
Net Income	-$23M	-$36M	+36.3%